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1) Department of Intensive Care Medicine, and 2) Department of Public Health, Erasmus Medical Centre, Rotterdam, The NetherlandsAbstractThe diagnostic use of procalcitonin for bacterial infections remains a matter of debate. Most studies have used ambiguous outcome measures
such as sepsis instead of infection. We performed a systematic review and meta-analysis to investigate the diagnostic accuracy of
procalcitonin for bacteraemia, a proven bloodstream infection. We searched all major databases from inception to June 2014 for
original, English language, research articles that studied the diagnostic accuracy between procalcitonin and positive blood cultures in
adult patients. We calculated the area under the summary receiver-operating characteristic (SROC) curves and pooled sensitivities and
speciﬁcities. To minimize potential heterogeneity we performed subgroup analyses. In total, 58 of 1567 eligible studies were included in
the meta-analysis and provided a total of 16 514 patients, of whom 3420 suffered from bacteraemia. In the overall analysis the area
under the SROC curve was 0.79. The optimal and most widely used procalcitonin cut-off value was 0.5 ng/mL with a corresponding
sensitivity of 76% and speciﬁcity of 69%. In subgroup analyses the lowest area under the SROC curve was found in
immunocompromised/neutropenic patients (0.71), the highest area under the SROC curve was found in intensive-care patients (0.88),
sensitivities ranging from 66 to 89% and speciﬁcities from 55 78%. In spite of study heterogeneity, procalcitonin had a fair diagnostic
accuracy for bacteraemia in adult patients suspected of infection or sepsis. In particular low procalcitonin levels can be used to rule out
the presence of bacteraemia. Further research is needed on the safety and efﬁcacy of procalcitonin as a single diagnostic tool to avoid
taking blood cultures.
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contributed equally to this studyIntroductionInfection and the subsequent sepsis syndrome are associated
with morbidity and mortality [1,2]. The fear of undertreatment
leads to the routine collection of specimens for microbiologicalMicrobiol Infect 2015; 21: 474–481
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.12.026culture and initiation of empiric antibiotic therapy [3]. On the
other hand, antibiotic overuse increases microbial selection and
resistance and can cause adverse drug reactions [4]. To assist
the diagnosis of infection in clinical practice its symptoms have
been grouped into the systemic inﬂammatory response syn-
drome (SIRS) [5]. A clinically suspected or proven infection in
the presence of SIRS is termed sepsis [5]. In recent years au-
thors have studied the use of biomarkers, like procalcitonin, to
improve the diagnosis of sepsis syndrome rather than of proven
infection [6–9]. The use of sepsis syndrome as a surrogate for
proven infection as an outcome parameter may be too sensitive
and non-speciﬁc. This could partially explain the contradicting
results in previous studies [6–10] and meta-analyses on the
diagnostic use of procalcitonin for sepsis [11–18].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Hoeboer et al. Procalcitonin for diagnosing bacteraemia 475The deﬁnition of proven local infection remains a matter of
debate and we therefore study the more robustly deﬁned
proven bloodstream infections, i.e. bacteraemia. Bacteraemia
can be identiﬁed in about 30% of septic patients and necessi-
tates further diagnostic evaluation [19]. However, culture re-
sults take several days and can be falsely negative in patients on
antibiotic treatment [20–22]. Recent studies demonstrated that
procalcitonin can accurately predict bacteraemia in patients
with community-acquired pneumonia [23], acute fever [24],
and in elderly patients suspected of infection [25]. Procalcitonin
can also accurately discriminate between true bacteraemia and
coagulase-negative staphylococci-contaminated blood cultures
[26]. Another study demonstrated that bacteraemia is unlikely
when procalcitonin levels are low [27]. Some meta-analyses
focused on the diagnostic value of procalcitonin for microbio-
logically conﬁrmed local infection [28–39] or bacteraemia [40].
However, the number of included studies was small, speciﬁc
patient subgroups were analysed, or studies concerning sepsis
were included as well [28–40].
We therefore performed a systematic review and meta-
analysis to investigate the diagnostic accuracy of procalcitonin
for bacteraemia. Our hypothesis is that in adult patients sus-
pected for infection or sepsis procalcitonin is a useful
biomarker of bacteraemia.MethodsSearch strategy and study selection
We used the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement for reporting this sys-
tematic review and meta-analysis [41]. A ﬂowchart of the
literature search can be found in the Supporting information
(Fig. S1). All prospective and retrospective, original, observa-
tional (case–control, cross-sectional, cohort and longitudinal)
studies published in English from inception until June 2014 were
considered eligible for inclusion. Studies were screened by title
and abstract and deﬁnite inclusion was decided upon after full
text review.
We included studies on adult hospitalized patients suspected
of infection or sepsis, in which bacteraemia with a known
pathogen was conﬁrmed by blood culture and measurement of
procalcitonin levels was performed within 24 hours of inclu-
sion. Studies had to give a detailed description of patient groups
and demographic variables. The comparison of procalcitonin
levels had to be between hospitalized patients with and without
bacteraemia, regardless of clinical symptoms. To be included for
analysis studies had to report the diagnostic accuracy estimates
of procalcitonin for bacteraemia; knowing area under the curve
(AUC), sensitivity, speciﬁcity and corresponding p-values. TheClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologycorresponding authors of eligible studies that did not provide
sufﬁcient data for meta-analysis were contacted to retrieve
additional data. We excluded case–control studies where
controls were healthy subjects, reviews, meta-analyses, case
reports, editorials, commentaries, letters, meeting abstracts,
poster presentations, animal studies and research performed in
children (< 18 years old). Two investigators (SHH and PJG)
independently evaluated all eligible studies for inclusion and
extracted the data. In case of disagreement a third investigator
(ABJG) was consulted.
Quality assessment
We used the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) tool [42], scores range from 0 to 14, to
assess the methodological quality of included studies.
Statistical methods
To avoid double inclusion of the same patient group we only
included one sensitivity and speciﬁcity from each article, unless
results clearly came from different patient groups. We used the
bivariate random-effects regression model for pooling the
sensitivity and speciﬁcity estimates, as recommended by the
Cochrane Diagnostic Test Accuracy Working Group [43]. The
bivariate model takes into account the potential trade-off be-
tween sensitivity and speciﬁcity by explicitly incorporating this
negative correlation in the analysis [44,45]. Cut-off values
differed among the included studies, the cut-off value closest to
0.5 ng/mL was used for the analysis if multiple cut-off values
were given. The 0.5 ng/ml cut-off was chosen based on rec-
ommendations of the manufacturer and current literature
[23,46–48], and was the cut-off used most often in the included
studies (Table 1). Summary receiver-operating characteristics
(SROC) curves were drawn using the bivariate model. The
closer the curve was to the upper left-hand corner of the
SROC curve plot, the better the overall accuracy of the test. An
area under the SROC curve between 0.90 and 1.0 is considered
as excellent diagnostic accuracy, between 0.80 and 0.90 as
good, between 0.70 and 0.80 as fair, between 0.60 and 0.70 as
poor and between 0.50 and 0.60 as fail [49]. We expected
substantial heterogeneity in the overall analysis and to obtain
more homogeneous results subgroup analyses were per-
formed. First, we calculated the diagnostic accuracy in speciﬁc
patient subgroups based on their underlying disease. We
calculated the diagnostic accuracy in studies comparing bac-
teraemia with non-bacteraemia in patients with SIRS and
comparing bacteraemia with non-bacteraemia in patients with
SIRS developing localized infections. When a speciﬁc subgroup
for the controls could not be identiﬁed we categorized the
study in the category non-bacteraemia. We studied the diag-
nostic accuracy of procalcitonin for bacteraemia inand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 474–481
TABLE 1. Study characteristics
Reference Country Inclusion criteria
Study
population
(n)
With
bacteraemia
(n)
Male
(%)
Age
(years) Department
Type of
patients Immunocompromised
Assay
type
Cut-off
values,
ng/mL QUADAS
Aalto 2004 [58] Finland Suspicion of systemic infection 92 13 48 52 ED Medical No 1 0.4 12
Albrich 2011 [59] Switzerland Performing blood culturesR 295 16 – 48 ED Medical No 2 0.15 12
Bell 2003 [60] Australia SIRS and suspicion of infection 123 12 66 61 ICU Mixed No 1 3.03 11
Bogar 2006 [61] Hungary New onset fever* 39 23 71 56 ICU Mixed Yes 1 N.A. 12
Bossink 1999 [62] Netherlands New onset fever 300 53 51 60 Ward Medical No 1 N.A. 12
Caterino 2004 [63] USA >65 years and performing blood cultures* 108 14 50 76 ED Medical No 1 0.5 13
Charles 2008 [64] France Critically ill with BSI and VAPR 161 117 58 65 ICU Mixed No 2 0.5 13
Chen 2011 [65] China Suspicion of catheter-related BSI 55 25 65 53 Mixed Medical No 1 3.1 12
Cheval 2000 [66] France Sepsis/ septic shock and no infection 60 9 57 58 Ward Mixed No 1 0.55 10
Chirouze 2002 [67] France Acute fever 165 22 58 58 Ward Medical No 1 0.12 12
Dwolatzky 2005 [68] Israel Proven microbial infection 187 16 30 83 ED Medical No 1 0.5 13
Engel 1999 [69] Germany Febrile neutropenia 44 15 – 47 Ward Medical Yes 1 0.51 11
Gac 2011 [70] France Febrile neutropenia* 29 10 53 56 Ward Medical Yes 3 0.5 11
Gaini 2007 [71] Denmark Suspicion of severe infection 154 34 50 61 Ward Medical No 2 2.19 13
Giamarellos 2001 [72] Greece Febrile neutropenia 115 28 70 56 Ward Medical Yes 1 0.5 11
Giamarellou 2004 [73] Greece Febrile neutropenia 158 52 56 52 Ward Medical Yes 2 1 11
Guinard-Barbier 2011 [52]. France Acute pyelonephritis* 347 58 8 33 ED Medical No 2 0.3 13
Ha 2013 [74] South
Korea
Acute pyelonephritisR 147 84 15 61 ED Medical No 4 0.5 12
Hoeboer 2012 [75] Netherlands New onset fever 101 12 68 64 ICU Mixed No 2 2.44 12
Hoenigl 2013 [53] Austria SIRS and suspicion of infection* 132 55 48 69 ED Medical No 4 N.A. 13
Hoenigl 2014 [76] Austria SIRS and performing blood cultures* 898 666 58 67 ED Medical No 3 0.5 12
Jeong 2012 [77] South
Korea
Suspicion of bacteraemia R 3343 331 59 65 Mixed Medical No 1 0.35 12
Jimeno 2004 [78] Spain Febrile neutropenia 104 15 38 58 Ward Medical Yes 1 0.5 11
Kallio 2000 [79] Finland Cancer and suspicion for infection 56 8 63 57 Ward Medical Yes 1 0.36 12
Karlsson 2010 [80] Finland Severe sepsis or septic shock 160 69 68 60 ICU Mixed No 3 1.2 14
Kim D 2011 [81] South
Korea
Febrile neutropenia 286 38 57 39 ED Medical Yes – 0.5 7
Kim M 2011 [24] South
Korea
Fever and performing blood cultures 252 31 44 54 ED Medical No 4 0.5 7
Koivula 2011 [82] Finland Febrile neutropenia 90 21 66 56 Ward Medical Yes 2 0.5 11
Lai 2010 [25] Taiwan SIRS and suspicion of infection 155 48 60 77 ED Medical No 2 0.38 13
Lee 2013 [83] South
Korea
PCT measurements R 357 199 53 66 Mixed Medical No 4 0.55 13
Liaudat 2001 [84] Switzerland Performing blood cultures 200 50 52 60 Mixed Mixed No 1 0.5 12
Loonen 2014 [85] Netherlands SIRS and suspicion of infectionR 125 27 60 65 ED Medical No 3 2.0 14
Mencacci 2012 [86] Italy Fever and suspicion of sepsis 1009 133 55 69 Mixed Mixed No 4 0.37 13
Menendez 2012 [54] Spain Pneumonia* 685 48 59 64 Ward Medical No 6 0.36 12
Muller 2010 [23] Switzerland Pneumonia* 925 73 59 73 ED Medical No 2 0.5 13
Munoz 2004 [87] Spain Fever 103 23 31 59 Ward Mixed No 1 0.1 11
Nakamura 2009 [88] Japan High fever suspicion of bacteraemia 116 65 65 59 ICU Mixed No 4 0.38 10
Nieuwkoop van 2010 [89] Netherlands Fever and urinary tract infection 581 131 38 66 Mixed Mixed No 2 0.5 13
Pereira 2013 [90] Portugal Pneumonia* 108 15 63 61 ICU Medical No 4 17 12
Persson 2004 [91] Sweden Febrile neutropenia 94 21 41 54 Ward Medical Yes 6 0.5 11
Prat 2008 [92] Spain Febrile neutropenia 61 19 51 47 Ward Medical Yes 2 0.5 8
Ratzinger 2014 [93] Austria Suspicion of infection and performing blood
cultures
298 75 58 58 Ward Mixed No – 0.35 13
Riedel 2011 [27] USA Signs of infection and performing blood culturesR 367 19 – 48 ED Medical No 2 0.15 14
Rintala 2001 [94] Finland Fever and a proven microbial infection 29 13 52 49 Mixed Medical No 1 <0.5 11
Robinson 2011 [95] Switzerland Febrile neutropenia 194 33 61 57 Ward Medical Yes 2 0.5 12
Romualdo 2014 [96] Spain SIRS and suspicion of infection 226 37 58 69 ED Medical No 3 0.45 13
Schuetz 2007 [26] Switzerland Positive blood cultures 19 7 65 63 Mixed Medical No 5 0.1 12
Schuetz 2008 [97] Switzerland Pneumonia 281 34 62 74 Ward Medical No 2 1.34 13
Shi 2013 [98] China New onset fever 106 60 67 64 ICU Mixed No 4 N.A. 12
Shomali 2012 [99] USA Cancer and new fever 248 30 57 56 ward Medical No 2 0.5 13
Su 2011 [100] Taiwan Performing blood cultures* 558 84 57 61 ED Medical No 1 0.5 12
Suarez-Santamaria 2010
[101]
Spain Proven microbial infection 205 36 58 65 ED Mixed No 6 N.A. 13
Theodorou 2012 [56] Greece Suspicion of catheter-related BSI* 46 26 61 48 ICU Mixed No 1 0.7 13
Tromp 2012 [102] Netherlands SIRS and suspicion of infection 342 55 56 59 ED Mixed No 2 0.5 13
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyimmunocompromised/neutropenic and immunocompetent pa-
tients separately. We categorized all studies according to
department of inclusion. Finally, we also studied retrospective
studies separately from prospective studies. We tested for a
threshold effect by adding a covariate for threshold to the
bivariate model.
We used IBM STATISTICS 21.0 (IBM SPSS, Chicago, IL, USA)
and R 3.1.1 (Vienna, Austria) to analyse the data. The R package
MADA was used to perform the pooling of sensitivity and
speciﬁcity and generating of SROC curves. Pooled sensitivity
and speciﬁcity estimates were generated, with their 95% CI. To
assess heterogeneity among studies I2 and χ2/Cochrane Q
statistics were performed. We used the Deeks funnel plot
asymmetry test to evaluate potential publication bias [50]. A
value of p < 0.10 for the slope coefﬁcient is considered as
signiﬁcant asymmetry, which indicates potential publication
bias. All other tests were two-sided and p < 0.05 was consid-
ered statistically signiﬁcant; exact values of p > 0.001 are given.ResultsLiterature search
The literature search found a total of 1567 articles, of which
1443 studies were excluded because of: written language other
than English (n = 118), age < 18 years (n = 759), in vitro/animal
studies (n = 57) or lack of original data (reviews, meta-analyses,
case reports, editorials, commentaries and letters, meeting
abstracts, poster presentations, n = 509). We performed a full
text review of the 124 articles considered eligible for inclusion,
which resulted in the exclusion of another 66 studies that did
not provide AUC values/sensitivity/speciﬁcity (n = 29), did not
study bacteraemia (n = 26), did not compare with non-
bacteraemia (n = 4), studied candidaemia (n = 3), used
healthy controls (n = 2), did not provide the procalcitonin level
for bacteraemia (n = 1), or used a longitudinal study design and
analysis (n = 1). The remaining 58 articles were used in the
meta-analysis. The complete reference list containing all
included and excluded studies is presented in the Supporting
information (Appendix S1). Table S1 (see Supporting
information) depicts the 66 studies excluded after full text
review.
Study characteristics and quality assessment
Table 1 provides some details of the included studies. In total,
16 514 patients were included, of whom 3420 had bacteraemia.
There was a slight tendency towards male preponderance. The
average age ranged from 33 to 77 years. Eight studies had a
retrospective and 50 a prospective study design. All 58 studies
provided AUC values, but only 49 studies provided sensitivityand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 474–481
FIG. 1. Summary receiver-operating characteristic (SROC) curve plot
of procalcitonin for the diagnosis of bacteraemia, including all studies
(n = 58). Individual studies are shown as open circles. Summary point is
shown as a closed square, representing sensitivity estimates pooled by
using bivariate random-effects regression model. The area under the
SROC curve (dashed line) is 0.79, pooled sensitivity is 76% and speciﬁcity
is 69%. The 95% conﬁdence region displays the 95% conﬁdence interval
of the pooled sensitivity and speciﬁcity. The 95% prediction region is the
region for a forecast of the true sensitivity and speciﬁcity in a future study.
TABLE 2. Accuracy estimates
Analysis AUC
Pooled
sensitivity
(95% CI)
Pooled
speciﬁcity
(95% CI)
Heterogeneity
(%)
I2
χ2/
Q p
Overall (n = 3420) 0.79 76 (72–80) 69 (64–72) 86% 1397 <0.001
Control group
Non-bacteraemia
(n = 1884)
0.78 72 (66–78) 74 (69–76) 88% 1070 <0.001
SIRS (n = 931) 0.78 76 (60–87) 66 (44–82) 83% 114 <0.001
Local infection and/or
sepsis (n = 605)
0.84 84 (80–87) 55 (47–63) 71% 162 <0.001
Immunocompromised/neutropenic
Yes (n = 320) 0.71 66 (54–76) 78 (71–83) 76% 120 <0.001
No (n = 3100) 0.79 79 (75–83) 65 (60–65) 81% 926 <0.001
Department
ICU (n = 399) 0.88 89 (79–94) 68 (57–77) 77% 54 <0.001
Mixed (n = 1009) 0.77 76 (65–85) 66 (57–76) 31% 501 <0.001
Ward (n = 587) 0.76 71 (63–78) 71 (64–77) 90% 433 <0.001
ED (n = 1425) 0.78 76 (69–82) 68 (61–75) 77% 285 <0.001
Study type
Prospective (n = 2507) 0.79 76 (71–80) 69 (64–73) 86% 721 <0.001
Retrospective (n = 913) 0.79 78 (66–86) 68 (56–78) 79% 636 <0.001
χ2/Q = χ2/Cochrane Q, CI = conﬁdence interval; ED = emergency department;
ICU = intensive care unit; mixed = ICU/ED/ward together; SIRS = systemic
inﬂammatory response syndrome.
478 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIand speciﬁcity. The cut-off values varied between 0.10 and 17
ng/mL. All samples for blood culture and procalcitonin mea-
surement were collected on inclusion or within 24 hours at the
emergency department, ward and/or intensive care unit. The
median QUADAS score was 12 (range 7–14); the per item
QUADAS scores are presented in Table S2 (see Supporting
information). Problematic QUADAS items were: the descrip-
tion of selection criteria and description of the execution of the
reference standard, whether the index test results were
interpreted without knowledge of the results of the referenceTABLE 3. 2 3 2 tables with corresponding sensitivity, speciﬁcity, P
Ward Emergency
BSI+ BSI– BSI+
PCT+ 7 26 33 6
PCT– 3 64 67 2
10 90 100 8
Prevalence 10%
Sensitivity 71%
Speciﬁcity 71%
PPV 21%
NPV 95%
BSI, blood stream infection; NPV, negative predictive value; PCT, procalcitonin; PPV, positiv
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectstandard and vice versa, reporting of uninterpretable/interme-
diate test results and the explanation of withdrawals.
The diagnostic accuracy of procalcitonin for
bacteraemia
In the overall analysis the area under the SROC curve was 0.79
(Fig. 1 and Table 2). The optimal and most widely used pro-
calcitonin cut-off value was 0.5 ng/mL (see Supporting
information, Table S3) and corresponded with a 76% sensi-
tivity and 69% speciﬁcity (Table 2). The sensitivity and speci-
ﬁcity per study are given in Fig. S2 (see Supporting information).
The lowest area under the SROC curve was found in immu-
nocompromised/neutropenic patients (0.71), the highest area
under the SROC curve (0.88) was found in ICU patients. The
lowest sensitivity was found in immunocompromised/neu-
tropenic patients (66), the highest in ICU patients (89). The
lowest speciﬁcity was found in patients with localized infections
(55) and the highest in immunocompromised/neutropenic pa-
tients (78). Table 3 shows the 2 × 2 tables with low positivePV and NPV
department Intensive care unit
BSI– BSI+ BSI–
29 35 11 28 39
63 65 1 60 61
92 100 12 88 100
8% 12%
76% 89%
68% 68%
17% 28%
97% 98%
e predictive value, +, positive test, −, negative test.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 474–481
CMI Hoeboer et al. Procalcitonin for diagnosing bacteraemia 479predictive values (17–28%) and high negative predictive values
(95–98%) for different hospital settings at the 0.5 ng/mL pro-
calcitonin cut-off. There was signiﬁcant heterogeneity in the
overall analysis and in most subgroups (Table 2). However,
there was no indication of a threshold-effect.
Evaluation of publication bias
Fig. S3 (see Supporting information) displays the Deeks funnel
plot asymmetry test of this meta-analysis. The Deeks test was
not statistically signiﬁcant (p 0.13), indicating that there is no
direct evidence for publication bias.DiscussionThis study evaluates the diagnostic accuracy of procalcitonin for
bacteraemia in different subgroups of adult hospitalized patients
suspected of infection or sepsis. Overall, at a cut-off level of 0.5
ng/mL, procalcitonin had a fair diagnostic accuracy for bacter-
aemia with an area under the SROC curve of 0.79. The pooled
AUC values of procalcitonin for the diagnosis of bacteraemia in
subgroups ranged from 0.71 to 0.88, with sensitivities ranging
from 66% in immunocompromised/neutropenic patients to
89% in ICU patients and speciﬁcities ranging from 55% in bac-
teraemia versus local infections to 78% in immunocompro-
mised/neutropenic patients. Based on these results low
procalcitonin levels in particular can be used to rule out the
presence of bacteraemia.
Two previous meta-analyses on the diagnostic accuracy of
procalcitonin for sepsis had contradicting conclusions while
having comparable results [12,18]. Tang et al. concluded that
there was no clear use for procalcitonin in diagnosing sepsis
(area under the SROC curve of 0.78, sensitivity of 71% and
speciﬁcity of 70%) [12]. However, their inclusion may be biased
by speciﬁcally excluding sepsis originating from certain types of
common infection sites [12]. In contrast, Wacker et al.
concluded that procalcitonin was useful for the diagnosis of
sepsis (area under the SROC curve 0.85, sensitivity 77%,
speciﬁcity 79%) [18]. They included studies on adult and pae-
diatric patients comparing sepsis to SIRS. Sepsis, however, was
deﬁned as clinically suspected or microbiologically proven
infection [18]. Two other meta-analyses studying the diagnostic
use of procalcitonin for bacterial infection found an area under
the SROC curve ranging from 0.82 to 0.89, sensitivity 83–88%,
speciﬁcity 81–83% [28,34]. Both analyses had comparable re-
sults but again contradicting conclusions. Simon et al. compared
C-reactive protein and procalcitonin in a meta-analysis on the
diagnostic accuracy in either proven or suspected bacterial
infection, favouring procalcitonin to be used in clinical practice
[28]. In contrast, Lee et al. contended that procalcitonin shouldClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologynot be used as single diagnostic tool for infection [34]. How-
ever, their conclusion was based on only four studies on the
diagnostic accuracy of procalcitonin for bacterial infection in
elderly patients [34]. As far as we know there is only one
previous meta-analysis on the diagnostic accuracy of procalci-
tonin for bacteraemia with an area under the SROC curve of
0.84, sensitivity 76% and speciﬁcity 70% [40]. This study
concluded that widespread use of procalcitonin is not recom-
mended because of the moderate diagnostic accuracy of pro-
calcitonin to predict bacteraemia [40]. This conclusion was
based on 17 included studies, of which not all contained bac-
teraemia as the primary endpoint. Even though previous meta-
analyses showed similar results, their conclusions differ,
possibly because of differences in interpretation of clinically
useful AUC values. In contrast to our study, the above-
mentioned meta-analyses only used a small selection of the
available literature or used sepsis syndrome and not microbi-
ologically documented infection as their endpoint. Our study
shows that procalcitonin can be used in the diagnostic process
of bacteraemia regardless of its clinical symptoms. As shown in
Table 3, low procalcitonin levels can be used to rule out the
presence of bacteraemia in different clinical settings.
This meta-analysis has several limitations. There is some
evidence for a concentration–response relation between pro-
calcitonin levels and probability of infection and disease severity
[51]. The deﬁnition of our primary outcome measure, bacter-
aemia, does not acknowledge such a concentration–response
relation. Only a minority of the studies in this meta-analysis
formally excluded patients treated with antibiotics before in-
clusion [23,24,52–56]. We cannot be certain that false-negative
results, due to possible antibiotic treatment before inclusion,
led to underestimation of the effect. Even though the effect size
is only fair (area under the SROC curve 0.79) its direction is
positive in almost all studies, in spite of heterogeneity. High
values of I2 are to be expected because of the variation in cut-
offs used in the different included studies and sensitivity and
speciﬁcity both depend on cut-offs. To homogenize the results
we attempted to use the sensitivities and speciﬁcities corre-
sponding with the cut-off value closest to 0.5 ng/mL if multiple
cut-off values were given. Other potential factors that could
have contributed to heterogeneity are variety in inclusion
criteria, underlying diseases, comorbidities, clinical course and
treatment before inclusion, variety in the control groups used
for comparison against bacteraemia, department of sample
collection, and differences in test performance of the various
procalcitonin assays. To reduce the inﬂuence of these factors
on heterogeneity we performed analyses in the supposedly
more homogeneous patient subgroups. As expected, substan-
tial heterogeneity remained in most subgroups. A Funnel plot
analysis based on the standard error of the natural logarithm ofand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 474–481
480 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIthe diagnostic odds ratio can be misleading, therefore we
evaluated potential publication bias using the recommended
effective sample size-based funnel plots and associated regres-
sion tests of asymmetry according to Deeks et al. [50].
In conclusion, this systematic review and meta-analysis shows
that procalcitonin has a fair diagnostic accuracy for bacteraemia
in adult, hospitalized patients suspected of infection or sepsis. In
particular low procalcitonin levels can be used to rule out the
presence of bacteraemia. Further research on the safety and
efﬁcacy of using procalcitonin as a single diagnostic tool to
withhold taking blood cultures remains to be proven.Transparency declarationNone to declare.Appendix A. Supplementary dataSupplementary data related to this article can be found at http://
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